Home What is Buprenorphine? Buprenorphine Products DATA Physician Locator DATA 2000 FAQs Notices Links En Español
Physician Waiver Qualifications Waiver Notification Form Ongoing Web-based Trainings Waived Physician WebBoard Update Physician Contact Information Model State Medical Board Policy
Buprenorphine Summits Articles SAMHSA Reports Other Gov't Reports
Nurses Guide to Buprenorphine Online Buprenorphine Course for Counselors
Medscape Medical News: For Prescription Opioid Dependence, Relapses Associated With Shorter Treatment Course
May 24, 2010 (New Orleans, Louisiana)In persons dependent on prescription opioids, tapering with buprenorphine during a 9-month period, whether initially or after a period of substantial improvement, led to nearly universal relapse in the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study.
DGDispatch: Buprenorphine Favoured Over Methadone for Opiate Addiction in Pregnancy: Presented at ACOG
May 19, 2010 (San Francisco, California) A recent study in Maine among women addicted to opiates has found that buprenorphine is safer for neonates than traditional treatment with methadone.
JAMA: Extended vs Short-term Buprenorphine-Naloxone for Treatment of Opioid-Addicted Youth
Nov. 5, 2008This clinical trial evaluates the efficacy of continuing Buprenorphine-Naloxone for 12 weeks versus detoxification for opioid-addicted youth. The number of patients younger than 18 years was too small to analyze separately, but overall, patients in the detox group had higher proportions of opioid-positive urine test results at weeks 4 and 8 but not at week 12.
Home | Accessibility | Privacy | Disclaimer | SAMHSA
Department of Health & Human Services | USA.gov
* Adobe™ PDF formatted files require the Adobe™ Reader to properly read them. Use this link to download this FREE program.